Dr. Yang, Pan-Chyr ’s Lab楊泮池 博士 實驗室


Our laboratory is aimed to explore the molecular mechanism of lung carcinogenesis and personalized therapy of lung cancer, which is the most important and endemic cancer in Taiwan. We focus on the following areas:

1. Functional genomics and translational research of lung cancer.
2. Molecular mechanism of EMT and cancer  metastasis.
3. Biomarker and personalized therapy of lung  cancer.

We have established lung cancer cell lines with different driver mutations and invasion/metastasis lung cancer cell line model. To reduce lung cancer mortality and improve treatment outcome, We establish national reference laboratory, provide standardized and high quality gene testing for all lung cancer patients. With the implementation of nation-wide gene testing and personalized therapy, the overall 5-year survival for NSCLC has been improved from 15.8% to 31.6% from 2009 to 2013. We also identified the susceptible gene loci for non-smoker lung adenocarcinoma in East Asia. Currently we are working on oncogenic mechanism and regulatory pathways involved in tumor progression and metastasis. We specifically focus on the EGFR signaling pathway. We are also developing new targeted therapy and decipher the mechanisms of drug resistance. We hope our discovery can provide further understanding of lung carcinogenesis and help to develop new therapeutics for lung cancer patients. 






Dr. Yang, Pan-Chyr
楊泮池 博士

Joint Appointment Research Fellow
(Joint Appointment with National Taiwan University)
Academician, Academia Sinica

M.D., Ph.D. National Taiwan University
  • TEL(lab):02-27899149 (Room No: 511)
  • FAX:02-27858594

  • Cell and Molecular Biology
  • Cancer genomics


Small-molecule PIK-93 modulates the tumor microenvironment to improve immune checkpoint blockade response
Science Advances, Apr 07, 2023
PM2.5 promotes lung cancer progression through activation of the AhR-TMPRSS2-IL18 pathway
EMBO Molecular Medicine, Mar 28, 2023
Stage Shift Improves Lung Cancer Survival: Real-World Evidence
Journal of Thoracic Oncology, Sep 18, 2022